Experimental Alzheimer's drug targets tau in Early-Stage patients
NCT ID NCT05469360
First seen Jun 05, 2026 · Last updated Jun 18, 2026 · Updated 2 times
Summary
This study tests a single injection of a drug called NIO752 in 38 adults aged 30-74 with early Alzheimer's or mild cognitive impairment due to Alzheimer's. The main goal is to see if the drug can lower levels of tau protein in the spinal fluid, which is linked to Alzheimer's damage. Researchers also monitor safety and side effects. This is an early-phase trial, so it focuses on biological changes and safety, not yet on symptom improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Kuopio, 70210, Finland
-
Novartis Investigative Site
Turku, 20520, Finland
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Paris, 75013, France
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Valencia, Valencia, 46017, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Barcelona, 08041, Spain
-
Novartis Investigative Site
Malmö, 221 85, Sweden
-
Novartis Investigative Site
Stockholm, 141 86, Sweden
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.